ClinicalTrials.gg
CompletedNCT01194804Updated Sep 17, 2019Results posted

E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

A Phase 2 interventional study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Alexion Pharmaceuticals, Inc.. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-09-17.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
13th of 18
27 · median 37
Started
2008
the only one that year
Phase 2
2 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
8 of 18
Alexion Pharmaceuticals, Inc.

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 13th largest by enrollment, is the only one that started in 2008, is one of 2 in phase 2, and was the 7th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

The objective of this study was to assess the long-term safety and efficacy of eculizumab in hemolytic PNH patients who completed the 4-week screening and 12-week treatment period of the C07-001 study. In addition, pharmacokinetic and pharmacodynamic assessments of eculizumab were conducted.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • Hemolytic Paroxysmal Nocturnal Hemoglobinuria
  • Eculizumab
  • PNH
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have fully completed C07-001 study 12-week treatment period

Exclusion criteria

Exclusion Criteria:

  • Patients who terminated early from the C07-001 study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol

    Drug: Eculizumab

Interventions

  • Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.

    Also known as: Soliris

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Lactate Dehydrogenase

    Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)

Secondary outcomes

  1. Change From Baseline in FACIT-Fatigue Scale Total Score

    The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.

    Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)

  2. Change From Baseline in PNH Red Blood Cell (RBC) Count

    Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)

  3. Change From Baseline in Number of Units of Packed RBCs Transfused

    Baseline is defined as the number of units transfused in 3 months prior to baseline

    Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)

  4. Change From Baseline in Plasma Free Hemoglobin

    Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)

07

Results

Posted Jul 12, 2019

Participant flow

Participant flow — Overall Study
MilestoneEculizumab
Started27
Completed26
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange From Baseline in Lactate Dehydrogenase
Time frame:
52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
Reported as:
Mean · Units/Liter
Change From Baseline in Lactate Dehydrogenase
Units/LiterEculizumab
Change From Baseline in Lactate Dehydrogenase-15.9 ± 1.20
Statistical analysis
  • Eculizumab · Sign test · p = <0.001
SecondaryChange From Baseline in FACIT-Fatigue Scale Total Score

The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.

Time frame:
52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
Reported as:
Mean · units on a scale
Change From Baseline in FACIT-Fatigue Scale Total Score
units on a scaleEculizumab
Change From Baseline in FACIT-Fatigue Scale Total Score8.0 ± 1.95
SecondaryChange From Baseline in PNH Red Blood Cell (RBC) Count
Time frame:
52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
Reported as:
Mean · cellsx10^12/L
Change From Baseline in PNH Red Blood Cell (RBC) Count
cellsx10^12/LEculizumab
Change From Baseline in PNH Red Blood Cell (RBC) Count0.51 ± 0.129
SecondaryChange From Baseline in Number of Units of Packed RBCs Transfused

Baseline is defined as the number of units transfused in 3 months prior to baseline

Time frame:
52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
Reported as:
Mean · units
Change From Baseline in Number of Units of Packed RBCs Transfused
unitsEculizumab
Change From Baseline in Number of Units of Packed RBCs Transfused-3.5 ± 1.43
SecondaryChange From Baseline in Plasma Free Hemoglobin
Time frame:
52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
Reported as:
Mean · mg/dL
Change From Baseline in Plasma Free Hemoglobin
mg/dLEculizumab
Change From Baseline in Plasma Free Hemoglobin-13.5 ± 8.55

Adverse events

Collected over From baseline (after first dose) to end of study (1 year).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab0/27 (0%)12/27 (44.4%)26/27 (96.3%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventEculizumab
PneumoniaInfections and infestations4/27
AnaemiaBlood and lymphatic system disorders2/27
PyrexiaGeneral disorders2/27
HaemolysisBlood and lymphatic system disorders1/27
ColitisGastrointestinal disorders1/27
CholelithiasisHepatobiliary disorders1/27
Jaundice cholestaticHepatobiliary disorders1/27
BronchitisInfections and infestations1/27
CellulitisInfections and infestations1/27
Gastroenteritis viralInfections and infestations1/27
Most frequent other events
Showing 10 of 27
Most frequent other events
EventEculizumab
NasopharyngitisInfections and infestations21/27
Upper respiratory tract infectionInfections and infestations6/27
Blood alkaline phosphatase increasedInvestigations6/27
HeadacheNervous system disorders6/27
GastroenteritisInfections and infestations5/27
DiarrhoeaGastrointestinal disorders4/27
PyrexiaGeneral disorders4/27
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders4/27
AnaemiaBlood and lymphatic system disorders3/27
Conjunctival haemorrhageEye disorders3/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Eculizumab
Mean48.3 ± 12.35
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female14
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eculizumab
Japanese27
Region of Enrollment
Region of Enrollment(Participants)Eculizumab
Japan27
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Ozawa K, Omine M. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol. 2013 Oct;98(4):406-16. doi: 10.1007/s12185-013-1404-y. Epub 2013 Aug 11. PubMed 23934275 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Sep 2010 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2019, 8 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Sep 3, 2010
Start
Apr 2008
Primary completionActual
Sep 2010
CompletionActual
Mar 2011
Results first posted
Jul 12, 2019
Last update
Sep 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01194804
Collaborators
CMIC Co, Ltd. Japan
Responsible party
Sponsor
First posted
Sep 3, 2010
Start date
Apr 2008
Primary completion
Sep 2010
Completion
Mar 2011
Results posted
Jul 12, 2019
Last update
Sep 17, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion